Detection in primary chronic myeloid leukaemia cells of p210BCR-ABL1 in complexes with adaptor proteins CBL, CRKL, and GRB2

Genes Chromosomes and Cancer

Volumn 45, Issue 12, 2006, Pages 1121-1129

  Patel, Hetal ^a   Marley, Stephen B ^a   Gordon, Myrtle Y ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; BCR ABL PROTEIN; CBL PROTEIN; CRK LIKE PROTEIN; HYDROLASE; PROTEIN GRB2; PROTEIN TYROSINE KINASE; PROTEINASE INHIBITOR;

ARTICLE; CELL LINE; CELL LYSATE; CELL PH; CHRONIC MYELOID LEUKEMIA; COMPLEX FORMATION; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVITY; ENZYME INHIBITION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LYSOSOME; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CASPASES; CELL LINE, TUMOR; CHLOROQUINE; FUSION PROTEINS, BCR-ABL; GRB2 ADAPTOR PROTEIN; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOPRECIPITATION; LEUKEMIA, MYELOID, CHRONIC; LEUKOCYTES, MONONUCLEAR; LYSOSOMES; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-CBL; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 33751104472     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20377     Document Type: Article

References (45)

1. Adams J. 2003. The proteasome: Structure, function, and role in the cell. Cancer Treat Rev 29:3-9.
2. Barnes DJ, Schultheis B, Adedeji S, Melo JV. 2005. Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia. Oncogene 24:6432-6440.
3. Bedi A, Zehnbauer B, Barber J, Sharkis S, Jones R. 1994. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 83:2038-2044.
4. Beran M, Pisa P, O'Brien S, Kurzrock R, Siciliano M, Cork A, Andersson BS, Kohl V, Kantarjian H. 1993. Biological properties and growth in SCID mice of a new myclogenous leukemia cell line (KBM-5) derived from chronic myclogenous leukemia cells in the blastic phase. Cancer Res 53:3603-3610.
5. Bhat A, Kolibaba K, Oda T, Ohno-Jones S, Heaney C, Druker BJ. 1997. Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells. J Biol Chcm 272:16170-16175.
6. Cortez D, Kadlec L, Pendergast AM. 1995. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol Cell Biol 15:5531-5541.
7. de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D, Spurr NK, Heisterkamp N, Groffen J, Stephenson JR. 1982. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 300:765-767.
8. Deininger MWN, Goldman JM, Melo JV. 2000. The molecular biology of chronic myeloid leukemia. Blood 96:3343-3356.
9. Di Bacco A, Cotter T. 2002. p53 Expression in K562 cells is associated with caspase-mediated cleavage of c-ABL and BCR-ABL protein kinases. Br J Haematol 117:588-597.
10. Dickmann D, Brill S, Garrett M, Totty N, Hsuan J, Monfries C, Hall C, Lim L, Hall A. 1991. Bcr encodes a GTPase-activating protein for p21rac. Nature 351:400-402.
11. Gaston I, Johnson KJ, Oda T, Bhat A, Reis M, Langdon W, Shen L, Deininger MW, Druker BJ. 2004. Coexistence of phosphotyrosine-dependent and -independent interactions between Cbl and Bcr-Abl. Exp Hematol 32:113-121.
12. Gishizky M, Cortez D, Pendergast A. 1995. Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation. Proc Natl Acad Sci USA 92:10889-10893.
13. Gordon M, Marley S, Apperley J, Marin D, Kaeda J, Szydlo R, Goldman JM. 2003. Clinical heterogeneity in chronic myeloid leukaemia reflecting biological diversity in normal persons. Br J Haematol 122:424-429.
14. Gordon MY, Dowding CR, Riley GP, Goldman JM, Greaves MF. 1987. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature 328:342-344.
15. Guo J, Wang J, Arlinghaua R. 1991. Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients. Cancer Res 51:3048-3051.
16. Hatch G, Oskin A, Vance D. 1993. Involvement of the lysosome in the catabolism of intracellular lysophosphatidylcholine and evidence for distinct pools of lysophosphatidylcholine. J Lipid Res 34:1875-1881.
17. Heisterkamp N, Groffen J, Stephenson JR, Spurr NK, Goodfellow PN, Solomon E, Carritt B, Bodmer WF. 1982. Chromosomal localization of human cellular homologues of two viral oncogenes. Nature 299:747-749.
18. Laneuville P. 1995. Abl tyrosine protein kinase. Semin Immunol 7:255-266.
19. Ma G, Lu D, Wu Y, Liu J, Arlinghaus R. 1997. Bcr phosphorylated on tyrosine 177 binds Grb2. Oncogene 14:2367-2372.
20. Marley S, Gordon M. 2005. Chronic myeloid leukaemia-Stem cell derived hut progenitor cell driven. Clin Sci (Lond) 109:13-25.
21. Maxwell S, Kurzrock R, Parsons S, Talpaz M, Gallick G, Kloetzer W, Arlinghaus R, Kouttab N, Keating M, Gutterman J. 1987. Analysis of p210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients. Cancer Res 47:1731-1739.
22. McWhirter J, Galasso D, Wang J. 1993. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol 13:7587-7595.
23. Montaner S, Perona R, Saniger L, Lacal JC. 1998. Multiple signalling pathways lead to the activation of the nuclear factor κ B by the Rho family of GTPases. J Biol Chem 273:12779-12785.
24. Nichols GL, Raines MA, Vera JC, Lacomis L, Tempst P, Golde DW. 1994. Identification of Crk1 as the constitutively phosphorylated 39-kDa tyrosine phosphoprotein in chronic myelogenous leukemia cells. Blood 84:2912-2918.
25. Nowell P, Hungerford D. 1960. A minute chromosome in human chronic granulocytic leukemia. Science 132:1497-1501.
26. Oda T, Heaney C, Hagopian J, Okuda K, Griffin J, Druker B. 1994. Crk1 is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 269:22925-22928.
27. Pelicci G, Lanfrancone L, Salcini A, Romano A, Mele S, Grazia Borrello M, Segatto O, Di Fiore P, Pelicci P. 1995. Constitutive phosphorylation of Shc proteins in human tumors. Oncogene 11:899-907.
28. Pendergast AM, Quilliam LA, Cripe G, Bassing CH, Dai X, Li N, Batzer A, Rabun KM, Der CJ, Schlessinger J. 1995. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75:175-185.
29. Posthuma E, van Bergen C, Kester M, de Paus R, van Veelen P, de Ru A, Drijfhout J, Lurvink E, Willemze R, Falkenburg JH. 2004. Proteosomal degradation of BCR/ABL protein can generate an HLA-A*0301-restricted peptide. but high-avidity T cells recognizing this leukemia-specific antigen were not demonstrated. Haematologica 89:1062-1071.
30. Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci P, Arlinghaus R, Pawson I. 1994. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 13:764-773.
31. Rozakis-Adcock M, McGlade J, Mbamalu G, Pelicci G, Daly H, Li W, Batzer A, Thomas S, Brugge J, Pelicci PG. 1992. Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases. Nature 360:689-692.
32. Salgia R, Uemura N, Okuda K, Li J-L, Pisick L, Sattler M, de Jong R, Druker B, Heisterkamp N, Chen LB, Groffen J, Griffin JD. 1995. CRKL links p210BCR-ABL with paxillin in chronic myelogenous leukemia cells. J Biol Chem 270:29145-29150.
33. Sattler M, Salgia R, Okuda K, Uemura N, Durstin M, Pisick E, Xu G, Li J, Prasad K, Griffin JD. 1996. The proto-oncogene product p120(CBL) and the adaptor proteins CRKL and c-CRK link c-ABL, p190(BCR/ABL) and p210(BCR/ABL) to the phosphatidylinositol-3 kinase pathway. Oncogene 12:839-846.
34. Schleuning M, Mittermuller J, Kolb M. 1999. BCR-ABL protein detection in peripheral blood mononuclear cells for follow-up of chronic myelogenous leukaemia patients. Eur J Haematol 62:149-154.
35. Schwartzberg PL, Stall AM, Hardin JD, Bowdish KS, Humaran T, Boast S, Harbison ML, Robertson EJ, Goff SP. 1991. Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations. Cell 65:1165-1175.
36. Shtivelman E, Lifshitz B, Gale RP, Canaani E. 1985. Fused transcript of abl and her genes in chronic myelogenous leukaemia. Nature 515:550-554.
37. Steelman L, Pohnert S, Shelton J, Franklin R, Bertrand F, McCubrey J. 2004. JAK/STAT, Raf/MEK/ERK, P13K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18:189-218.
38. ten Bosch GJA, Kessler JH, Blom J, Joostan AM, Gambacorti-Passerini C, Melief CJM, Leeksma OC. 1998. BCR-ABL oncoprotein is expressed by platelets from CML patients and associated with a special pattern of CRKL phosphorylation. Br J Haematol 103:1109-1115.
39. ten Hoeve J, Kaartinen V, Fioretos T, Haataja L. 1994. Cellular interactions of CRKL, an SH2-SH3 adaptor protein. Cancer Res 54:2563-2567.
40. ten Floeve J, Morris C, Heisterkamp N, Groffen J. 1993. Isolation and chromosomal localization of CRKL, a human crk-like gene. Oncogene 8:2469-2474.
41. Tybulewicz VLJ, Crawford CE, Jackson PK, Bronson RT, Mulligan RC, 1991. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 65:1153-1163.
42. Van Etten R. 1999. Cycling, stressed out and nervous:Cellular functions of c-Abl. Trends Cell Biol 9:179-186.
43. Van Etten RA, Jackson P, Baltimore D. 1989. The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. Cell 58:669-678.
44. Voneken JW, Schaick H, Kaartinen V, Deemer K, Coates T, Landing B, Pattengale P, Dorseuil O, Bokoch GM, Groffen J, Heisterkamp N. 1995. Increased neutrophil respiratory burst in bcr-null mutants. Cell 80:719-728.
45. Wetzler M, Talpaz M, Van Etten R, Hirsh-Ginsberg C, Beran M, Kurzrock R. 1993. Subcellular localization of Bcr, Abl and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J Glin Invest 92:1925-1939.